U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07794501) titled 'Markers of Efficacy to Immunotherapy in Patients With Metastatic Melanoma' on Aug. 25.
Brief Summary: Cutaneous melanoma is an aggressive malignancy with a rising global incidence; its prognosis has been radically transformed by immune checkpoint inhibitors (ICIs), a class of immunotherapeutic agents targeting immune regulatory pathways such as programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and lymphocyte activation gene 3 (LAG-3). Currently approved first-line treatment strategies-including anti-PD-1 monotherapy and the combinations of nivolumab plus ipilimumab and nivolumab plus relat...